Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease

Trial Profile

Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2009

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Huntington's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Amarin Neuroscience
  • Most Recent Events

    • 23 Apr 2009 New trial record.
    • 09 Apr 2009 Results from this trial will be used to support a Marketing Authorisation Application with the European Medicines Agency for ethyl eicosapentaenoic acid in patients with Huntington's disease, according to a Amarin Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top